Polycystic Ovary Syndrome (PCOS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Polycystic Ovary Syndrome (PCOS) Market Outlook

Thelansis’s “Polycystic Ovary Syndrome (PCOS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polycystic Ovary Syndrome (PCOS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Polycystic Ovary Syndrome (PCOS) Overview

Polycystic Ovary Syndrome (PCOS) is a prevalent metabolic disorder characterized by hormonal imbalances in women of reproductive age (between 12 and 51 years). It is associated with elevated levels of male hormones, leading to irregular menstrual cycles, ovulation difficulties, and potential challenges with conception. Additionally, PCOS can manifest as abnormal hair growth on the body and face and may have long-term implications, such as an increased risk of heart disease and diabetes. The etiology of PCOS remains incompletely understood; nevertheless, several significant factors have been identified, including:

1. Excessive Insulin Production: Elevated insulin levels may stimulate the production of androgens, normally present in lower quantities in females, resulting in ovulation problems.
2. Excessive Androgen Production: The ovaries produce abnormally high levels of androgen hormones, leading to acne and hirsutism (excessive hair growth on the face and body).
3. Low-Grade Inflammation: Recent studies indicate that females with PCOS experience low-grade inflammation, contributing to increased androgen production and potential cardiovascular issues.
4. Heredity: There is evidence of a genetic correlation among women affected by PCOS.

Common signs and symptoms of PCOS in females include irregular menstruation (oligomenorrhea), skipped or absent menstruation (amenorrhea), heavy menstrual bleeding (menorrhagia), excessive hair growth on various body areas, acne, weight gain, hair loss, and skin darkening in specific regions. Only a few agents have received approval from the U.S. Food and Drug Administration specifically for treating polycystic ovary syndrome. Several agents are contraindicated during pregnancy. Insulin-sensitizing agents are recommended for most women with PCOS as they positively affect insulin resistance, menstrual irregularities, anovulation, hirsutism, and obesity. Among these agents, metformin has the most extensive data supporting its effectiveness. Additionally, rosiglitazone and pioglitazone have effectively reduced hirsutism and insulin resistance. Metformin and clomiphene, combined, are considered first-line treatments for inducing ovulation. Furthermore, insulin-sensitizing agents, oral contraceptives, spironolactone, and topical eflornithine may be utilized to manage hirsutism in affected patients.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Polycystic Ovary Syndrome (PCOS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034